** Shares of vaccine maker Novavax NVAX.O rise 13% to $7.06 premarket
** Co says its COVID-19 vaccine is "approvable based on conversations with the U.S. Food and Drug Administration (FDA)"
** NVAX also says it has received a request from the FDA for a commitment to provide additional clinical data on its vaccine if it secures an approval
** The FDA had missed its deadline for making a decision on traditional approval for co's protein-based shot earlier this month
** Up to last close, stock had fallen 22.3% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。